Issue 119 • June 2022

How ambitious are the emissions targets of pharma and biotech companies?

CMO agreements need to go public, but ‘glib’ onshoring not the answer

Should Covid-19 clinical trial plans still centre around EUAs?

In association with

Continuous manufacturing cautiously builds on hype

Covid-19 and a drive for sustainability back the move to continuous manufacturing, but large-scale investment drags

In association with

02/23/2024 23:27:05
  • Home | Continuous manufacturing cautiously builds on hype
  • In this issue
  • CSafe Global
  • Contents
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • SHL Medical Company Insight
  • SHL Medical
  • WR Grace
  • Comment
  • CMO agreements need to go public, but ‘glib’ onshoring not the answer
  • Biologic sales forecast to pass innovative small molecule sales in next five yea
  • The telemedicine community has rallied to provide support to patients in Ukraine
  • Osteoarthritis pipeline shifting from analgesics to disease-modifying treatments
  • BioLife Solutions
  • Mimotopes Company Insight
  • Mimotopes
  • In Depth
  • Continuous manufacturing builds on hype but adoption remains gradual
  • Can Relmada’s fast-acting pill for major depressive disorder compete in
  • Access to CAR-T therapies in Central and Eastern Europe in “catch-up” mode compa
  • How ambitious are the emissions targets of pharma and biotech companies?
  • Should Covid-19 clinical trial plans still centre around EUAs?
  • BEA Technologies
  • Datwyler Company Insight
  • Datwyler
  • In Data
  • Top and emerging locations for M&A deals in the pharma industry
  • Deals relating to genomics increased in the pharma industry in H2 2021
  • Pharma industry companies are increasingly innovating in machine learning
  • Baxter
  • Events
  • Next issue
06/01/2022 00:00:00